Evolent Health, Inc · NYSE:EVH
Evolent Health — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
22 slides from Evolent Health's conference presentation, Jan 14, 2025
Slide 1: Investor Presentation
Investor Presentation 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025
Slide 2: Disclaimers
Disclaimers Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). These include statements relating to future actions, tre
Slide 3: A unifying focus on better health outcomes
A unifying focus on better health outcomes At Evolent, we bring a simple but powerful perspective to our work: We believe every person deserves the same quality of care we would want for our loved ones. Working across specialties and primary care, we seek to improve the care journey for members diag
Slide 4: The Evolent investment case is rooted in three pillars
The Evolent investment case is rooted in three pillars supporting positive member outcomes Evolent is a differentiated platform for Specialty Condition Management • Specialty care is large unmet need in today’s healthcare landscape = Total Specialty $150B 1 TAM for Evolent. • Evolent’s solutions see
Slide 5: Recent updates on near-term business headwinds and tailwinds
Recent updates on near-term business headwinds and tailwinds 1 Expected Company Specific Tailwinds Anticipated Sector-Wide Headwinds • Macro environment increasing demand for low-abrasion, clinical- • Managed care industry continues to navigate through generational focused specialty condition manage
Slide 6: The opportunity in value-based specialty care
The opportunity in value-based specialty care Large Specialty TAM with Low Penetration Significant Customer Unmet Need Health plan customers facing challenging cycle of lower pricing, unfavorable risk adjustment $150B Premium Headwinds changes, and membership dynamics → Specialty management is a key
Slide 7: Evolent platform overview
Evolent platform overview Key Strategic Themes Focus on value-based approach to drive quality up and manage cost (e.g., MD alignment, patient Oncology Cardiology MSK Chronic / PCP navigation, deep clinical Deep Multi- differentiation). Specialty Imaging, Genetics, Therapy Expertise Surgical Manageme
Slide 8: Foundation to high-value condition management starts with precision pathways
1 Clinical Decision Support ONCOLOGY EXAMPLE Evolent’s foundation to high-value condition management starts with precision (“Level 1”) pathways ROOTED IN CLINICAL EVIDENCE TUNED FOR THE PATIENT COST TRANSPARENCY DRIVES SAVINGS Anti-Cancer Regimens Average Cost Per Treatment1 Level 2 Pathways Example
Slide 9: Evolent's foundational decision support platform drives sustainable clinical behavior change
1 Clinical Decision Support Evolent’s foundational decision support platform drives sustainable clinical behavior change with low network abrasion TECH-ENABLED PLATFORM POINT OF CARE VALUE OPPORTUNITIES • Purpose-built, clinician-centric portal for decision support and • Appropriate use recommendati
Slide 10: The Evolent performance model promotes physician engagement and support
2 Provider Alignment ONCOLOGY EXAMPLE The Evolent performance model promotes physician engagement and support to optimize care outcomes and costs PEER-TO-PEER ENGAGEMENT OUTCOME OF TREATMENT PLANS1 OUTCOME OF INTERVENTIONS2 81% Oncologists who change their • Subspecialty-matched peer-to-peer (P2P) m
Slide 11: Clinically-trained care navigation professionals drive member engagement
3 Member Journey Clinically-trained care navigation professionals drive member engagement programs designed to benefit members Evolent Navigators Licensed social workers and clinicians who engage members via phone and internet Member Journey Member Program Care Navigation Advance Care Planning • Mem
Slide 12: Improving care through peer-to-peer conversations
Improving care through peer-to-peer conversations Determination • Evolent reviewer noted that a baseline echocardiogram was not done • The reviewer reached out for a peer-to-peer Peer-to-Peer • Patient’s oncologist realized that an echocardiogram was not done • Evolent reviewer educated oncologist o
Slide 13: Specialty condition management revenue models comparison
Evolent specialty condition management revenue models comparison Note: historical data as reported for the quarter ended September 30, 2024. Margin target % and PMPM as previously disclosed in investor materials, most recently on June 4, 2024. Specialty Technology & Specialty Performance Services Su
Slide 14: Performance Suite: Key contract changes secured
Performance Suite: Key contract changes secured Goals established Nov 2024: Progress as of Jan 2025: 1. Increase reimbursement rates to cover • ~600,000 members moving to T&S suite effective 1/1/2025 (partner 1 higher incidence and medical costs: commitment to commence discussions to re-enter PS ris
Slide 15: Adjusting the features of our Performance Suite product
Adjusting the features of our Performance Suite product Performance Suite Models Traditional Adjusted ✓Evolution in model modestly reduces long- Total value creation opportunity to health term mature margin 20%+ 20%+ plan and Evolent expectation in exchange for Modestly lower, mechanical, annual Tar
Slide 16: Sizing near-term expected headwinds and tailwinds to 2025 Adjusted EBITDA
Sizing near-term expected headwinds and tailwinds 1 to 2025 Adjusted EBITDA Expected EVH Specific Tailwinds Anticipated Sector-Wide Headwinds ~$100-105MM ($25MM) ($20MM) Achieved targeted $100M in Estimate of potential impact Estimate of potential expected earnings from outsized increase in impact m
Slide 17: Reiterating Long-Term Outlook
Reiterating Long-Term Outlook 1 Full 2025 outlook to be disclosed on February 20 , 2025 ✓ Continued balanced approach to growth – targeting strong expansion in both Specialty Technology & Services (T&S) and Performance Suite (PS) solutions. Organic Growth ✓ Long term target: maintain prior 15%+ annu
Slide 18: We bring a simple but powerful perspective to our work: We believe every person
We bring a simple but powerful perspective to our work: We believe every person deserves the same quality of care we would want for our loved ones. Working across specialties and primary care, we seek to improve the care journey for members diagnosed with cancer, cardiovascular diseases, musculoskel
Slide 19: Appendix
evolent Appendix
Slide 20: Appendix: full member journey oncology example
Appendix: full member journey oncology example TOPOTECAN LURBINECTEDIN Multiple NCCN-approvable Median overall survival, months 8 9 CONTEXT drugs with clear data on clinical Median progression-free survival, months 4 3.5 inferiority versus alternate Objective remission rate % 30 30 regimens QUARTERL
Slide 21: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to disclosing financial results that are determined in accordance with GAAP, we present and discuss certain non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance. Adjusted EBITDA is defined as
Slide 22: How we calculate product type: PMPM, lives, cases, target mature flow-through margin
How we calculate product type: PMPM, lives, cases, target mature-flow through margin % and $(PMPM) and new revenue agreements Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members manag
Evolent Health — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix